Bob Nelsen

Texas-Based Colossal Achieves Unicorn Status With $150M Series B Raise, Plans To ‘De-Extinct’ the Dodo Bird

by | Jan 31, 2023
Colossal says its efforts could help boost "the U.S. high-tech advantage." Its gene editing technologies "will make waves across sectors—in agriculture with new biofuels and preserving biodiversity, as well as in human health through improved gene therapy and vaccine development," the company said.
MORE